Abstract
Drug delivery to the airway and lower respiratory tract by aerosol inhalation has become a successful, non-invasive method of preventing and treating local disease of the lung. Consequently, it has been a promising route for clinical trials using highly specific and novel therapies to overcome viral pulmonary infection such as RNA interference, neutralising monoclonal antibodies and microparticle treatments. Yet despite this great potential, this form of delivery has proven somewhat ineffective due to airway remodeling, inflammation and mucus hypersecretion that results from viral symptoms in the respiratory tract. Here we review the research into the delivery technologies available as well as the types of therapeutics used for respiratory virus disease and examine how virus infection-induced airway inflammation modulates its success. We discuss the future of aerosol administration and present potential alternative methods for efficient drug delivery so as to improve postinfection virus control therapies.
Keywords: Airway, drug delivery, infection, inhalation, therapeutics, virus.
Current Drug Delivery
Title:Targeted Drug Delivery to the Virus-Infected Airway; Complications and Remedies
Volume: 12 Issue: 1
Author(s): Daniel T.W. Clarke and Nigel A.J. McMillan
Affiliation:
Keywords: Airway, drug delivery, infection, inhalation, therapeutics, virus.
Abstract: Drug delivery to the airway and lower respiratory tract by aerosol inhalation has become a successful, non-invasive method of preventing and treating local disease of the lung. Consequently, it has been a promising route for clinical trials using highly specific and novel therapies to overcome viral pulmonary infection such as RNA interference, neutralising monoclonal antibodies and microparticle treatments. Yet despite this great potential, this form of delivery has proven somewhat ineffective due to airway remodeling, inflammation and mucus hypersecretion that results from viral symptoms in the respiratory tract. Here we review the research into the delivery technologies available as well as the types of therapeutics used for respiratory virus disease and examine how virus infection-induced airway inflammation modulates its success. We discuss the future of aerosol administration and present potential alternative methods for efficient drug delivery so as to improve postinfection virus control therapies.
Export Options
About this article
Cite this article as:
Clarke T.W. Daniel and McMillan A.J. Nigel, Targeted Drug Delivery to the Virus-Infected Airway; Complications and Remedies, Current Drug Delivery 2015; 12 (1) . https://dx.doi.org/10.2174/1567201811666140918114528
DOI https://dx.doi.org/10.2174/1567201811666140918114528 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Peptide Mimetics Looking for a Turn to Block Aberrant Players of Malignancy
Current Cancer Therapy Reviews Current and Future Development of Estrogen Receptor Ligands: Applications in Estrogen-Related Cancers
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Targeting the Voltage-Dependent K+ Channels Kv1.3 and Kv1.5 as Tumor Biomarkers for Cancer Detection and Prevention
Current Medicinal Chemistry Genetics of Chronic Obstructive Pulmonary Disease
Current Respiratory Medicine Reviews Role of Metabolic Enzymes P450 (CYP) on Activating Procarcinogen and their Polymorphisms on the Risk of Cancers
Current Drug Metabolism Is Brain-Derived Neurotrophic Factor: A Common Link Between Neurodegenerative Disorders and Cancer?
Current Alzheimer Research Bioengineered 3D Scaffolds in Cancer Research: Focus on Epithelial to Mesenchymal Transition and Drug Screening
Current Pharmaceutical Design Chemotherapy with si-RNA and Anti-Cancer Drugs
Current Drug Delivery <i>Ajuga</i> L.: A Systematic Review on Chemical Composition, Phytopharmacological and Biological Potential
Current Bioactive Compounds The Role of Systemic Treatment and Radiotherapy in Malignant Mesothelioma
Current Respiratory Medicine Reviews Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma
Current Medicinal Chemistry Biological Activity of Carotenoids: Its Implications in Cancer Risk and Prevention
Current Pharmaceutical Biotechnology MiR-509-3-5p-NONHSAT112228.2 Axis Regulates p21 and Suppresses Proliferation and Migration of Lung Cancer Cells
Current Topics in Medicinal Chemistry The Role of the Oxysterol/EBI2 Pathway in the Immune and Central Nervous Systems
Current Drug Targets Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner
Current Drug Metabolism Synthesis and Biological Evaluation of 1, 3-Dihydroxyxanthone Mannich Base Derivatives as Potential Antitumor Agents
Letters in Drug Design & Discovery Antimicrobial Activity of New 2-Thioxo-benzo[g]quinazolin-4(3H)-one Derivatives
Medicinal Chemistry Interactions Between Proteins and Platinum-Containing Anti-Cancer Drugs
Mini-Reviews in Medicinal Chemistry Oxaliplapin and Capecitabine (XELOX) Based Chemotherapy in the Treatment of Metastatic Colorectal Cancer: The Right Choice in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Antibodies Against Muscarinic Receptors in Breast Cancer: Agonizing Tumor Growth
Current Immunology Reviews (Discontinued)